Home > Annual Financials > NATCO PHARMA

NATCO PHARMA Financial Statement Analysis
[BOM: 524816|NSE : NATCOPHARM]

The Revenues of NATCO PHARMA have increased by 10.77% YoY .
The Earnings Per Share (EPS) of NATCO PHARMA has decreased by -24.76 % YoY.
COMMUNITY POLL
for NATCO PHARMA
Please provide your vote to see the results

NATCO PHARMA Last 5 Annual Financial Results
[BOM: 524816|NSE : NATCOPHARM]

ConsolidatedMar2026
Mar2025
Mar2024
Mar2023
Mar2022
Revenues ₹4,430 Cr₹3,999 Cr₹2,707 Cr₹1,945 Cr₹2,052 Cr
Expenses ₹2,236 Cr₹2,247 Cr₹1,795 Cr₹1,681 Cr₹1,448 Cr
Operating Profit (Excl OI) ₹2,194 Cr₹1,751 Cr₹912 Cr₹264 Cr₹604 Cr
Other Income ₹357 Cr₹128 Cr₹129 Cr₹99 Cr₹106 Cr
Interest ₹24 Cr₹19 Cr₹15 Cr₹18 Cr₹13 Cr
Depreciation ₹235 Cr₹187 Cr₹164 Cr₹143 Cr₹117 Cr
Profit Before Tax ₹2,291 Cr₹1,674 Cr₹862 Cr₹202 Cr₹580 Cr
Profit After Tax ₹1,883 Cr₹1,388 Cr₹715 Cr₹170 Cr₹442 Cr
Consolidated Net Profit ₹1,885 Cr₹1,388 Cr₹715 Cr₹170 Cr₹441 Cr
Earnings Per Share (Rs)₹79.25₹105.33₹77.56₹39.19₹9.32
PAT Margin (%)29.2039.5432.0524.837.67
ROE(%)16.3027.9825.8815.664.06
ROCE(%)17.1632.8530.0818.064.86
Total Debt/Equity(x)0.080.040.060.030.09

Key Financials

Market Cap : ₹ 16,029.5 Cr
Revenue (TTM) : ₹ 3,088.9 Cr
Net Profit(TTM) : ₹ 669.3 Cr
EPS (TTM) : ₹ 34.1
P/E (TTM) : 23.9

Industry Peers & Returns1W1M1Y
NATCO PHARMA -1.4% 4% 0.9%
SUN PHARMACEUTICAL INDUSTRIES 1% 7.5% 7.9%
DIVIS LABORATORIES 0.8% 22.8% 71.4%
TORRENT PHARMACEUTICALS 0.2% 1.9% 20.9%
CIPLA 1.5% 6.4% -7.8%
DR REDDYS LABORATORIES 0.8% 12.2% 12.3%
MANKIND PHARMA 1.3% 16.8% 17.2%
LUPIN 1.9% 4.3% -2.6%
ZYDUS LIFESCIENCES 0.5% 5.3% 28.4%


NATCO PHARMA Revenues
[BOM: 524816|NSE : NATCOPHARM]

Y-o-Y

10.77 %

5 Yr CAGR

21.21 %

Years Revenues % Change
Mar2026 ₹4,430 Cr
10.77
Mar2025 ₹3,999 Cr
47.72
Mar2024 ₹2,707 Cr
39.20
Mar2023 ₹1,945 Cr
-5.23
Mar2022 ₹2,052 Cr -


NATCO PHARMA Operating Profit
[BOM: 524816|NSE : NATCOPHARM]

Y-o-Y

25.26 %

5 Yr CAGR

38.06 %

Years Operating Profit % Change
Mar2026 ₹2,194 Cr
25.26
Mar2025 ₹1,751 Cr
92.10
Mar2024 ₹912 Cr
246.00
Mar2023 ₹264 Cr
-56.36
Mar2022 ₹604 Cr -

Operating Margins
Y-o-Y

13.08 %

5 Yr CAGR

13.91 %

Years Operating Margin% % Change
Mar2026 49.53%
13.08
Mar2025 43.8%
30.05
Mar2024 33.68%
148.56
Mar2023 13.55%
-53.94
Mar2022 29.42% -

NATCO PHARMA Profit After Tax
[BOM: 524816|NSE : NATCOPHARM]

Y-o-Y

35.81 %

5 Yr CAGR

43.80 %

Years Profit After Tax % Change
Mar2026 ₹1,885 Cr
35.81
Mar2025 ₹1,388 Cr
94.09
Mar2024 ₹715 Cr
320.76
Mar2023 ₹170 Cr
-61.44
Mar2022 ₹441 Cr -

PAT Margins
Y-o-Y

-26.15 %

5 Yr CAGR

39.68 %

Years PAT Margin(%) % Change
Mar2026 29.2 %
-26.15
Mar2025 39.54 %
23.37
Mar2024 32.05 %
29.08
Mar2023 24.83 %
223.73
Mar2022 7.67 % -

NATCO PHARMA Earnings Per Share (EPS)
[BOM: 524816|NSE : NATCOPHARM]

Y-o-Y

-24.76 %

5 Yr CAGR

70.76 %

Years EPS % Change
Mar2026 ₹79
-24.76
Mar2025 ₹105
35.80
Mar2024 ₹78
97.91
Mar2023 ₹39
320.49
Mar2022 ₹9.32 -

NATCO PHARMA Return on Capital Employed (ROCE)
[BOM: 524816|NSE : NATCOPHARM]

Y-o-Y

-47.76 %

5 Yr CAGR

37.08 %

Years ROCE % Change
Mar2026 17.16%
-47.76
Mar2025 32.85%
9.21
Mar2024 30.08%
66.56
Mar2023 18.06%
271.60
Mar2022 4.86% -

NATCO PHARMA Share Price vs Sensex

Current Share Price : ₹817.0
Current MarketCap: ₹ 16,029.5 Cr
Updated EOD on :Nov 20,2026

Share Price Returns(%) 1 Week 1 Month 1 Year
NATCO PHARMA

-1.4%

4%

0.9%

SENSEX

2.9%

13.9%

-0.8%

NATCO PHARMA related INDICES

BSE Indices1W1M1Y
BSE 500 1.6% 10.5% 1%
BSE 1000 1.3% 9.9% 1.3%
BSE HEALTHCARE 0.7% 12.4% 19.3%
BSE 400 MIDSMALLCAP INDEX -0.3% 6.4% 1.6%
BSE 250 SMALLCAP INDEX -0.8% 4.5% 2%
NSE Indices1W1M1Y
NIFTY 500 1.5% 10.3% 1.1%
NIFTY TOTAL MARKET 1.3% 9.9% 1.3%
NIFTY500 HEALTHCARE INDEX 1.2% 13.2% 19.6%
NIFTY500 MULTICAP 50:25:25 1% 9.1% 2%
NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX 0.6% 8% 2.5%

You may also like the below Video Courses


FAQ about NATCO PHARMA Financials


How the annual revenues of NATCO PHARMA have changed ?

The Revenues of NATCO PHARMA have increased by 10.77% YoY .

How the Earnings per Share (EPS) of NATCO PHARMA have changed?

The Earnings Per Share (EPS) of NATCO PHARMA has decreased by -24.76 % YoY .